NAL Pharmaceutical Group Limited

Yes. Pursuant to the statutory registers of the Hong Kong Companies Registry, NAL Pharmaceutical Group Limited was officially incorporated on 1997-01-13 as a Private company limited by shares (standing for 29 years). Official cross-departmental records confirm its current legal status is [Live / In Operation], maintaining valid operational standing under Hong Kong law (Verified: September 2026).

Under Hong Kong's Unique Business Identifier (UBI) regime, NAL Pharmaceutical Group Limited is identified by two official registration numbers: its 8-digit Business Registration Number (BRN / UBI) [20766494] administered by the Inland Revenue Department, and its 7-digit Company Registration Number (CRN) [0588356] maintained by the Companies Registry for historical statutory filings.

Pursuant to Sections 627 and 643 of the Hong Kong Companies Ordinance (Cap. 622), the equity ownership and executive board of NAL Pharmaceutical Group Limited are governed by its statutory Register of Members and Register of Directors. Any appointment or resignation of directors or the company secretary must be filed within 15 days via Form ND2A, while complete shareholder equity ratios are disclosed annually in Form NAR1. Furthermore, under Section 653H of Cap. 622, the company must maintain a Significant Controllers Register (SCR) for persons holding over 25% beneficial interest or voting rights.

Yes. According to the official statutory records of the Hong Kong Companies Registry, NAL Pharmaceutical Group Limited has officially recorded 3 legal name change(s): [WELL CREATION LIMITED (煒創有限公司) (effective 1997-01-13)], [NEXMED (ASIA) LIMITED (尼克美製葯(亞洲)有限公司) (effective 1997-04-04)], [NAL Pharma (China) Limited (安能泰製藥有限公司) (effective 2012-01-09)]. Pursuant to Sections 107 and 109 of the Companies Ordinance (Cap. 622), each name change was passed by special resolution (Form NNC2) and took statutory effect upon issuance of a Certificate of Change of Name by the Registrar of Companies; under Section 109(4), changing the company name does not affect any rights, obligations, or legal proceedings of the company.

Official records of the Hong Kong Companies Registry verify that NAL Pharmaceutical Group Limited maintains a cumulative statutory archive of 10 filing record(s) on file (latest statutory filing indexed on 2026-01-16: Form NAR1 - Annual Return (2026) (English)). Under Section 662 of the Companies Ordinance (Cap. 622), the corporation's active governance and equity standing are documented through Annual Returns (Form NAR1), constitutional Articles of Association (A&A), and statutory officer or capital update filings (Form ND2A / Form NSC1), all accessible as official barcoded image dossiers.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Officially licensed by Hong Kong statutory authorities, currently holding: Department of Health (DH Licensed Dealer) (Licence No. 6/2A/2016); 2. Judicial Screening (Litigation & Winding-Up): no compulsory winding-up petitions (HCCW) or public High Court / District Court litigation writs were identified for NAL Pharmaceutical Group Limited in current public judicial indexing. For major cross-border M&A or credit facilities, an up-to-the-minute court registry search is recommended.

Official filings of the Hong Kong Companies Registry record the statutory registered office of NAL Pharmaceutical Group Limited at: [ROOM 401, 4/F, 93-103 WING LOK STREET, SHEUNG WAN, HONG KONG]. Official registry dossiers also record 1 statutory registered office address change filing(s) (Form NR1). Under Section 658 of the Companies Ordinance (Cap. 622), a document or court writ may be lawfully served on a company by leaving it at, or sending it by post to, this registered office. Where the address is domiciled at a licensed TCSP company secretary's premises, Cap. 622B Section 3 permits statutory name display via a compliant electronic signboard system.

Unlike jurisdictions with government ICP domain licensing, Hong Kong regulates corporate identity disclosure under Section 4 of the Companies (Disclosure of Company Name and Liability Status) Regulation (Cap. 622B): NAL Pharmaceutical Group Limited must legibly display its exact registered name on all business letters, contracts, invoices, and any company website, and report its website (if any) in its Annual Return (Form NAR1) or Form NR2. To prevent cross-border impersonation, trade partners should authenticate the company's legal standing via its statutory identifiers (CRN: 0588356 / 8-digit BRN: 20766494) and barcoded Companies Registry dossiers rather than unverified external web pages.